84.50 0.00 (0.00%)
Pre-Market: 8:08AM EDT
|Bid||0.00 x 1200|
|Ask||0.00 x 3000|
|Day's Range||84.40 - 85.87|
|52 Week Range||64.72 - 126.98|
|Beta (3Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||105.65|
Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NBIX are favorable, with net inflows of $3.55 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and opicapone, an investigational adjunct treatment for Parkinson's disease. Analyses include long-term data on INGREZZA in adult patients with TD, a disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Live Audio Webcast will be on June 11, 2019 SAN DIEGO , June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference ...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Neurocrine...
SAN DIEGO, May 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019, in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.
MONTREAL , May 21, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that ORILISSA™ (elagolix) 200 mg twice daily is now available.
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the effect of involuntary movements (possible TD) on patient health-related quality of life. Results from the study showed that involuntary movements had a significant negative impact on a patient's health-related quality of life, with nearly 30% of patients with possible TD reporting moderate-to-extreme problems performing their usual activities, including work, housework and leisure activities.
SAN DIEGO, May 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD), an involuntary movement disorder. Neurocrine will also present new long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, highlighting the overall effect of treatment with INGREZZA on the abnormal movements associated with TD based on additional items from the Abnormal Involuntary Movement Scale (AIMS), including overall severity of abnormal movements, incapacitation due to abnormal movements and patient awareness of abnormal movements and distress level.
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 14, 2019, in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.
- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on ...
SAN DIEGO and CAMBRIDGE, Mass., May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson's disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson's disease.
SAN DIEGO, May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel, once-daily, oral, selective, peripherally-acting catechol-O-methyltransferase (COMT) inhibitor for the treatment of Parkinson's disease. The analysis found that treatment with opicapone 50 mg, added to levodopa, resulted in a significant and sustained increase in ON time without troublesome dyskinesia1, in Parkinson's disease patients with motor fluctuations. The analysis, which included data from more than 900 patients in the double-blind, placebo-controlled Phase III BIPARK-1 and BIPARK-2 studies, was highlighted as an oral session at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia.
- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders - Analysis of Phase III ...
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Opicapone in Parkinson’s DiseaseIn its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?Stock price movementsNeurocrine Biosciences (NBIX) reported first-quarter results on April 29. The company reported total revenues of $138.40 million, a YoY rise of 94.70%. Posted
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
The San Diego-based company said it had a loss of $1.12 per share. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss ...